Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome.

Triptorelin 0.2 mg and leuprolide 1 mg subcutaneous injections for triggering final follicular maturation were compared in patients with a high risk for ovarian hyperstimulation syndrome (OHSS). Infertile patients treated with GnRH antagonist protocol between January 2014 and March 2016 were recruited. Patients with high serum oestradiol levels on HCG day (>3000 pg/ml) indicating a risk of OHSS consisted of the study groups (A and B). Patients with serum oestradiol levels less than 3000 pg/ml consisted of the control group (C). A single injection of 0.2 mg triptorelin, 1 mg leuprolide and 10000 IU HCG were administered for final oocyte triggering in groups A (n = 63), B (n = 74) and C (n = 131), respectively. Demographic parameters were comparable between the groups. No cases of severe or moderate OHSS occurred in any group. The clinical pregnancy rates were 31.7%, 37.8% and 32.8% in groups A, B and C, respectively. Both injections had comparable efficacy in clinical outcome and OHSS risk. Regardless of preferred drug, GnRH agonist trigger for final oocyte maturation seems to be safe for patients with high OHSS risk, and can be safely used in fresh embryo transfer cycles.

Ischaemia-modified albumin in preeclampsia: A critical view.

The aim of the study was to compare ischaemia-modified albumin (IMA) levels, both original and corrected, in healthy pregnancies and pregnancies complicated with preeclampsia. Maternal and cord blood samples from study (n = 16) and control (n = 17) groups were collected at the time of delivery. IMA levels were given in absorbance units (ABSU). IMA levels, both original and corrected, were compared between study and control groups. No significant difference was found between maternal and cord blood IMA levels between the study and control groups [1.0 (0.3-3.5) vs 1.2 (0.2-1.4) ABSU, p = .053 and 1.0 (0.1-2.2) vs 0.9 (0.4-3.6) ABSU, p = .382, respectively]. The results were similar for maternal IMA levels, after correction of IMA levels [1.1 (0.3-5.1) vs 1.2 (0.2-1.6) ABSU, p = .292]. IMA is a novel marker for ischaemia, without precise conclusions about its value in preeclampsia. An absolute correction formula, considering all possible intervening factors, is required for more accurate results.

The association between prolactin, high-sensitivity C-reactive protein and Framingham risk score in menopause.

AIMS: To evaluate the association between serum prolactin, high-sensitivity C-reactive protein (hs-CRP) levels and cardiovascular disease risk in postmenopausal women regarding the Framingham Risk Score (FRS). METHODS: Fifty-eight menopausal women were enrolled into the cross-sectional study. All participants had 24-hour ambulatory blood pressure monitoring, echocardiography, electrocardiography, and carotid intima-media thickness measurement. Blood samples were obtained for prolactin, hs-CRP, lipid profile, fasting glucose, and insulin. RESULTS: Among the participants, 67.24% had a FRS <10%, and 32.75% had a FRS ≥10%. Levels of prolactin and hs-CRP did not differ between the FRS groups. In the FRS <10% group, significantly higher levels of prolactin were found. Cases with hypertension have significantly higher levels of hs-CRP. Prolactin and hs-CRP were found to be associated with hypertension in the FRS <10% and ≥10% groups, respectively. CONCLUSIONS: Hypertensive postmenopausal women with low risk for cardiovascular diseases have increased levels of prolactin, suggesting a possible role in the pathogenesis of hypertension. The correlation of hs-CRP with systolic blood pressure can be interpreted as a potential effect of hypertensive heart disease reflecting a state of high-risk milieu with elevated inflammatory markers.

Diminished ovarian reserve in patients with psoriasis.

OBJECTIVE: Psoriasis is a multi-systemic chronic inflammatory skin disease. Previous data suggests that women with some chronic inflammatory diseases have diminished ovarian reserve. This study explores ovarian reserve in patients with psoriasis. MATERIALS AND METHODS: We prospectively analyzed 14 female patients with psoriasis and 35 healthy age and body mass index matched controls. An interview explored demographic characteristics, obstetrical history and menstrual characteristics. Psoriatic area severity index (PASI) in patients was assessed. Estrogen, follicle-stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone and with gynecologic ultrasonography, ovarian volume and antral follicular count (AFC) were measured in both study and control groups. These values were analyzed with changes of the PASI in the patient group. RESULTS: Patients with psoriasis had significantly higher levels of FSH and FSH/LH ratio than healthy controls (p = 0.039, p = 0.005 respectively). AFC of psoriasis patients were significantly lower than healthy controls (p = 0.002).There were no significant difference among other hormone levels and ovarian volumes (p > 0.05). The hormone levels, ovarian volume and AFC were not correlated with PASI of the patients. CONCLUSION: The results of the study suggest that patients with psoriasis may have diminished ovarian reserve.

Collagen cross-links as a marker for subclinical atherosclerosis in postmenopausal women.

OBJECTIVE: This study aimed to examine the utility of pyridinoline (Pyd) and deoxypyridinoline (Dpd) cross-links in the detection of subclinical atherosclerosis in postmenopausal women with or without osteoporosis. METHODS: We measured Pyd, Dpd, carotid intima-media thickness (CIMT), fasting total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and blood pressure in 59 healthy postmenopausal women: 30 had normal bone mineral density (group I) and the remaining 29 had osteoporosis or osteopenia (group II) according to World Health Organization criteria. RESULTS: There were no statistically significant differences in age, duration of menopause, age at menopause, lipid profile, body mass index, Pyd level, Dpd level, and Pyd-to-Dpd ratio between the groups (P > 0.05). No significant difference in CIMT was found when groups I and II were compared (P = 0.538). No statistically significant differences in Pyd level, Dpd level, and Pyd-to-Dpd ratio were found when women with CIMT higher than 5 mm and women with CIMT of 5 mm or less were compared in groups I and II (P > 0.05). However, significantly declined Dpd level and increased Pyd-to-Dpd ratio were found in women with CIMT higher than 5 mm when compared with women with CIMT of 5 mm or less. CIMT was found to be negatively correlated with Dpd level (r = -0.346, P = 0.007) and to be positively correlated with the Pyd-to-Dpd ratio (r = 0.702, P < 0.001). CONCLUSIONS: The increase in the Pyd-to-Dpd ratio, irrespective of the participants' bone mineral density, may have predictive value in the determination of subclinical atherosclerosis in postmenopausal women.